Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RVPH 
Reviva Pharmaceuticals Holdings Inc. (RVPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RVPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.57% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 31.34M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 6 | Beta -0.05 | 52 Weeks Range 0.30 - 2.99 | Updated Date 08/29/2025 |
52 Weeks Range 0.30 - 2.99 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.13 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -173.7% | Return on Equity (TTM) -916.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21051595 | Price to Sales(TTM) - |
Enterprise Value 21051595 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6 | Shares Outstanding 68003600 | Shares Floating 60916276 |
Shares Outstanding 68003600 | Shares Floating 60916276 | ||
Percent Insiders 7.27 | Percent Institutions 21.07 |
Upturn AI SWOT
Reviva Pharmaceuticals Holdings Inc.
Company Overview
History and Background
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Founded to address unmet needs in schizophrenia, depression, and other neurological conditions.
Core Business Areas
- CNS Drug Development: Reviva focuses on developing and commercializing novel therapeutics for schizophrenia, depression, and other CNS disorders. Their lead product candidates target unmet medical needs in these areas.
Leadership and Structure
The leadership team is comprised of experienced pharmaceutical executives and scientists. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments dedicated to research, development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Bucinazine (Brilaroxazine): Bucinazine is Reviva's lead product candidate, an investigational drug for the treatment of schizophrenia. Currently in clinical trials. Market share is currently 0 as it is not approved for sale. Competitors include antipsychotics like risperidone, olanzapine, quetiapine, and aripiprazole from companies like Johnson & Johnson (JNJ), Eli Lilly (LLY), and AstraZeneca (AZN).
- RP5063: RP5063 is another investigational drug for pulmonary hypertension and idiopathic pulmonary fibrosis (IPF). Currently in preclinical to early clinical stages. Market share is currently 0 as it is not approved for sale. Competitors in pulmonary hypertension include drugs from United Therapeutics (UTHR) and Johnson & Johnson (JNJ). Competitors in IPF include drugs from Boehringer Ingelheim and Roche.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on CNS disorders, is characterized by high regulatory hurdles, lengthy development timelines, and significant investment in research and development. The market for schizophrenia and depression treatments is substantial, driven by the prevalence of these conditions.
Positioning
Reviva is a clinical-stage biopharmaceutical company aiming to develop novel therapies for CNS disorders. Its competitive advantage lies in its novel drug candidates with potentially differentiated mechanisms of action compared to existing treatments.
Total Addressable Market (TAM)
The global market for schizophrenia treatment is estimated to be billions of dollars annually. Reviva aims to capture a portion of this TAM with bucinazine. The market for pulmonary hypertension and IPF are also significant, each with billion-dollar valuations. Reviva is positioned to address specific patient segments within these markets.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced leadership team
- Potential for differentiated mechanisms of action
- Focus on unmet medical needs
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Regulatory approval of bucinazine
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent expirations
- Market access challenges
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- AZN
- UTHR
- RHHBY
Competitive Landscape
Reviva's advantages include its novel drug candidates, but it faces significant competition from established pharmaceutical companies with greater resources and approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advancing drug candidates through preclinical and clinical development. There's been no significant revenue growth to date.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates would be required for specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include advancing bucinazine through Phase 3 clinical trials and exploring new indications for its drug candidates.
Summary
Reviva Pharmaceuticals is a clinical-stage company with promising drug candidates for CNS disorders. Its success hinges on positive clinical trial results and regulatory approval. The company faces substantial competition and financial risks but has the potential for significant growth if its lead drug candidates are approved. Investors should carefully consider the risks and uncertainties associated with clinical-stage biopharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in clinical-stage biopharmaceutical companies involves significant risks, including the risk of complete loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Reviva Pharmaceuticals Holdings Inc.
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2018-10-18 | Founder, CEO, President & Director Dr. Laxminarayan Bhat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.revivapharma.com |
Full time employees 14 | Website https://www.revivapharma.com | ||
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.